Cipla clarified that its supply partner Pharmathen received nine USFDA Form 483 observations during a November 2025 ...
Freedom of Information Act requests filed with the Food and Drug Administration by hedge funds last month revealed big financial players closely eyeing warning letters, enforcement documents, and ...
Cipla had earlier received final USFDA approval in May 2024 to market its generic Lanreotide injection in multiple strengths.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback